BURNING ROCK BIOTECH LTD-ADR (BNR) Forecast, Price Target & Analyst Ratings

NASDAQ:BNRUS12233L2060

Current stock price

18.57 USD
-0.55 (-2.88%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BURNING ROCK BIOTECH LTD-ADR (BNR).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release Date
Mar 23, 2026

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $18.57 to mean target of N/A, Based on 5 analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

Analyst Ratings & History

Current Analyst Ratings

BNR Current Analyst RatingBNR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

BNR Historical Analyst RatingsBNR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
BNR was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about BNR.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed BNR. So this is just the average opinion of a couple of analysts.

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2021-07-14CICCInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
Mar 23, 2026

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

Full Analyst Estimates 2025 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
BNR revenue by date.BNR revenue by date.
563.238M
10.90%
537.435M
-4.58%
515.822M
-4.02%
1.219B
136.32%
1.142B
-6.32%
1.311B
14.80%
1.494B
13.96%
1.69B
13.12%
1.9B
12.43%
EBITDA
YoY % growth
BNR ebitda by date.BNR ebitda by date.
-856.311M
-14.28%
-535.921M
37.42%
-270.232M
49.58%
N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
BNR ebit by date.BNR ebit by date.
-980.407M
-23.00%
-669.321M
31.73%
-322.432M
51.83%
-460.73M
-42.89%
44.115M
109.58%
117.64M
166.67%
197.47M
67.86%
261.54M
32.45%
336.12M
28.52%
Operating Margin
BNR operating margin by date.BNR operating margin by date.
-174.07%-124.54%-62.51%-37.80%3.86%8.97%13.22%15.48%17.69%
EPS
YoY % growth
BNR eps by date.BNR eps by date.
N/A
28.57%
N/A
22.37%
N/A
95.52%
-7.17
-277.41%
N/AN/AN/AN/AN/A

All data in CNY

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in CNY

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BNR Yearly Revenue VS EstimatesBNR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
BNR Yearly EPS VS EstimatesBNR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -20 -40 -60

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
16.85%
Revenue Next 5 Year
15.51%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

BURNING ROCK BIOTECH LTD-ADR / BNR Forecast FAQ

Can you provide the upcoming earnings date for BURNING ROCK BIOTECH LTD-ADR?

BURNING ROCK BIOTECH LTD-ADR (BNR) will report earnings on 2026-03-23, after the market close.

Can you provide the consensus rating for BURNING ROCK BIOTECH LTD-ADR stock?

The consensus rating for BURNING ROCK BIOTECH LTD-ADR (BNR) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.